Role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in the management of bone and soft-tissue metastases

J Bone Joint Surg Br. 2010 Mar;92(3):419-23. doi: 10.1302/0301-620X.92B3.23131.

Abstract

We retrospectively reviewed 71 histopathologically-confirmed bone and soft-tissue metastases of unknown origin at presentation. In order to identify the site of the primary tumour all 71 cases were examined with conventional procedures, including CT, serum tumour markers, a plain radiograph, ultrasound examination and endoscopic examinations, and 24 of the 71 cases underwent 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography (FDG-PET). This detected multiple bone metastases in nine patients and the primary site in 12 of the 24 cases; conventional studies revealed 16 primary tumours. There was no significant difference in sensitivity between FDG-PET and conventional studies. The mean maximal standardised uptake value of the metastatic tumours was significantly higher than that of the primary tumours, which is likely to explain why FDG-PET did not provide better results. It was not superior to conventional procedures in the search for the primary site of bone and soft-tissue metastases; however, it seemed to be useful in the staging of malignancy.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biopsy
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / pathology
  • Bone Neoplasms / secondary*
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms, Unknown Primary / diagnostic imaging*
  • Neoplasms, Unknown Primary / pathology
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Retrospective Studies
  • Soft Tissue Neoplasms / diagnostic imaging
  • Soft Tissue Neoplasms / pathology
  • Soft Tissue Neoplasms / secondary*
  • Young Adult

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18